Back to Treatments

Treatment

Secukinumab

2
Conditions
164
Trials
28K
Participants
59%
Average Safety

Condition Evidence

Ankylosing Spondylitis

23 trials · 10K participants

68% effectiveness · 60% safety

Psoriasis

141 trials · 18K participants

85% effectiveness · 58% safety
Secukinumab | DFDA